Skip to main navigation

Immunocore

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

Primary Menu

Overview
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Annual Reports
IR Resources

News Releases

Breadcrumb

Home /
Investor Relations /
News & Events /
News Releases

Year

9 November 2021

Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

18 October 2021

Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel

22 September 2021

Immunocore announces publication of phase 3 data comparing tebentafusp with investigator’s choice in The New England Journal of Medicine

20 September 2021

Immunocore presents data at the European Society for Medical Oncology (ESMO) Congress 2021 demonstrating a reduction in circulating tumor DNA (ctDNA) while on tebentafusp is associated with overall survival in the Phase 2 clinical trial

13 September 2021

Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021

10 September 2021

Immunocore to present at upcoming investor conferences

8 September 2021

Immunocore Announces UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

24 August 2021

Immunocore Announces that U.S. Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma

11 August 2021

Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update

4 June 2021

Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Pagination

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Displaying 51 - 60 of 174

Site - Shareholder Tools

Immunocore

Site - Footer Social

About us
Our science
Our therapy areas
For patients

News
Careers
Contact us

Privacy and Social Media Guidelines
Cookies
Payments and Disclosures
Clinical trials

©2023 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd